micro-community-banner
Profile Image
  • Add Media
  • Saved

1yr
Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN - PubMed

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38598969/

Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment...

Homozygous familial hypercholesterolemia requires early lipid-lowering treatment. Lipoprotein apheresis effectively reduces LDL-C, but guidelines are limited. A consensus statement offers practical guidance on its use in children with this condition.

Profile Image
  • Saved

1yr
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review - PubMed

Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38265575/

Based on reported willingness to pay thresholds for each setting, most CEA studies concluded that screening for FH compared with no screening was cost-effective, regardless of the screening strategy. Cascade...

This review synthesizes cost-effectiveness of familial hypercholesterolemia screening strategies, finding cascade screening most cost-effective, with long-term lipid-lowering treatment costs as a key ICER driver. Most strategies were cost-effective compared to no screening.

Profile Image
  • Saved

1yr
American Heart Association Scientific Sessions

The American Heart Association 2024 Scientific Sessions were held at the McCormick Place Convention Center in Chicago from Nov. 16 to 18. More than 15,000 attendees were at the meeting via virtual stream or in-person. Click above to find our postconference wrap-up report with insights on new therapies and advances in preventing, diagnosing, and treating cardiovascular disease.

  • Saved

1yr
Targeting dysregulated lipid metabolism in the tumor microenvironment - PubMed

Targeting dysregulated lipid metabolism in the tumor microenvironment - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38060103/

The reprogramming of lipid metabolism and its association with oncogenic signaling pathways within the tumor microenvironment (TME) have emerged as significant hallmarks of cancer. Lipid metabolism is defined as a...

Lipid metabolism dysregulation in the tumor microenvironment influences cancer progression. This review explores mechanisms of lipid reprogramming, its role in oncogenesis, and emerging therapies targeting lipid metabolism for cancer treatment.

Profile Image
  • Saved

1yr
Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: A randomized crossover trial - PubMed

Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: A randomized crossover trial - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39168095/

Non-alcoholic fatty liver disease (NAFLD) affects 25% of the adult population with no effective drug treatments available. Previous animal studies reported that a polyphenol-rich extract from the Amazonian berry camu-camu...

A randomized trial showed that camu-camu (CC) polyphenol-rich extract reduced liver fat by 7.43%, improved liver enzymes, and altered gut microbiota composition in overweight adults, potentially lowering NAFLD risk.

Profile Image